<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">35305353</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-095X</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title><ISOAbbreviation>Phytomedicine</ISOAbbreviation></Journal><ArticleTitle>Inhibitory effect of tanshinone IIA, resveratrol and silibinin on enterovirus 68 production through inhibiting ATM and DNA-PK pathway.</ArticleTitle><Pagination><StartPage>153977</StartPage><MedlinePgn>153977</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2022.153977</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0944-7113(22)00055-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human enterovirus 68 (EV68) is a primary etiological agent for respiratory illnesses, while no effective drug has yet used in clinics largely because the pathogenesis of EV68 is not clear. DNA damage response (DDR) responds to cellular DNA breaks and is also involved in viral replication. Three DDR pathways includes ataxia telangiectasia mutated (ATM), ATM and Rad3-related (ATR), and DNA-dependent protein kinase (DNA-PK). Natural products proved to be an excellent source for the discovery and isolation of novel antivirals. Among them, tanshinone IIA, resveratrol, silibinin, rutin and quercetin are reported to target DDR, therefore their roles in anti-EV68 are investigated in this study.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study investigated the anti-EV68 ability of various natural compounds related to DDR.</AbstractText><AbstractText Label="STUDY DESIGN AND METHODS" NlmCategory="METHODS">The methods include cell counting, flow cytometry, western blot, Immunofluorescence staining, comet assays, quantitative real-time RT PCR and short interfering RNAs (siRNAs) for analysis of cell number, cell cycle, protein expression, protein location, DNA damage, mRNA level and knock down target gene, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">EV68 infection induced DDR. Down-regulation or inhibition of ATM or DNA-PK lowered DDR in EV68-infected cells and mitigated viral protein expression, however, down-regulation or inhibition of ATR unexpectedly up-regulated DDR, and promoted viral protein expression. Meanwhile tanshinone IIA, resveratrol, and silibinin inhibited ATM and/or DNA-PK activation and decreased viral proliferation, while rutin and quercetin inhibited ATR activation and promoted viral production. The role of them in ATM, DNA-PK and ATR activation was consistent with previous reports.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Tanshinone IIA, resveratrol and silibinin inhibited EV68 proliferation through inhibiting ATM and/or DNA-PK activation, and they were effective anti-EV68 candidates.</AbstractText><CopyrightInformation>Copyright Â© 2022 The Author(s). Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Jilin University, Changchun, China; Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Science, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, The First Hospital of Jilin University, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xiao-Yan</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Science, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Wen-Bo</ForeName><Initials>WB</Initials><AffiliationInfo><Affiliation>Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Science, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shao-Hua</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huan</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yu-Meng</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Science, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jin-Ming</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Science, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Min-Na</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Science, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin-Hua</ForeName><Initials>XH</Initials><AffiliationInfo><Affiliation>Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Science, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jing-Hua</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Jilin University, Changchun, China; Center for Pathogen Biology and Infectious Diseases, The First Hospital of Jilin University, Jilin University, Changchun, China. Electronic address: jinghuayu@jlu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Phytomedicine</MedlineTA><NlmUniqueID>9438794</NlmUniqueID><ISSNLinking>0944-7113</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DNA damage response</Keyword><Keyword MajorTopicYN="N">Enterovirus 68</Keyword><Keyword MajorTopicYN="N">Resveratrol</Keyword><Keyword MajorTopicYN="N">Silibinin</Keyword><Keyword MajorTopicYN="N">Tanshinone IIA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>19</Day><Hour>20</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35305353</ArticleId><ArticleId IdType="doi">10.1016/j.phymed.2022.153977</ArticleId><ArticleId IdType="pii">S0944-7113(22)00055-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle>